Alpha Tau to Participate in March Investor Conferences
Alpha Tau Medical (NASDAQ: DRTS), developer of the Alpha DaRT® alpha-radiation cancer therapy, has announced its participation in upcoming investor conferences for March 2025. The company's CFO, Raphi Levy, will be presenting and available for one-on-one investor meetings.
Investors interested in scheduling meetings with Mr. Levy can coordinate through their representatives at Investor Summit Group, Oppenheimer, and Sidoti. The conferences represent an opportunity for investors to learn more about Alpha Tau's innovative cancer treatment technology and business developments.
Alpha Tau Medical (NASDAQ: DRTS), sviluppatore della terapia al Alpha DaRT® a radiazione alfa per il cancro, ha annunciato la sua partecipazione a prossime conferenze per investitori a marzo 2025. Il CFO dell'azienda, Raphi Levy, presenterà e sarà disponibile per incontri individuali con gli investitori.
Gli investitori interessati a pianificare incontri con il signor Levy possono coordinarsi attraverso i loro rappresentanti presso Investor Summit Group, Oppenheimer e Sidoti. Le conferenze rappresentano un'opportunità per gli investitori di conoscere meglio la tecnologia innovativa di trattamento del cancro di Alpha Tau e gli sviluppi aziendali.
Alpha Tau Medical (NASDAQ: DRTS), desarrollador de la terapia de cáncer Alpha DaRT® con radiación alfa, ha anunciado su participación en próximas conferencias para inversores en marzo de 2025. El CFO de la empresa, Raphi Levy, estará presentando y disponible para reuniones individuales con los inversores.
Los inversores interesados en programar reuniones con el Sr. Levy pueden coordinar a través de sus representantes en Investor Summit Group, Oppenheimer y Sidoti. Las conferencias representan una oportunidad para que los inversores conozcan más sobre la innovadora tecnología de tratamiento del cáncer de Alpha Tau y los desarrollos empresariales.
알파 타우 메디컬 (NASDAQ: DRTS), 알파 다르트® 알파 방사선 암 치료의 개발자는 2025년 3월에 열릴 예정인 투자자 회의에 참여한다고 발표했습니다. 회사의 CFO인 라피 레비(Raphi Levy)가 발표를 하고 투자자와의 일대일 미팅을 위해 자리를 마련할 것입니다.
레비 씨와의 미팅을 원하는 투자자들은 Investor Summit Group, Oppenheimer 및 Sidoti를 통해 그들의 대표자와 조율할 수 있습니다. 이 회의는 투자자들이 알파 타우의 혁신적인 암 치료 기술과 사업 발전에 대해 더 많이 알 수 있는 기회를 제공합니다.
Alpha Tau Medical (NASDAQ: DRTS), développeur de la thérapie contre le cancer à Alpha DaRT® par radiation alpha, a annoncé sa participation à des conférences pour investisseurs prévues en mars 2025. Le CFO de l'entreprise, Raphi Levy, présentera et sera disponible pour des réunions individuelles avec les investisseurs.
Les investisseurs intéressés à planifier des réunions avec M. Levy peuvent se coordonner par l'intermédiaire de leurs représentants auprès de Investor Summit Group, Oppenheimer et Sidoti. Les conférences représentent une opportunité pour les investisseurs d'en apprendre davantage sur la technologie innovante de traitement du cancer d'Alpha Tau et les développements commerciaux.
Alpha Tau Medical (NASDAQ: DRTS), Entwickler der Alpha DaRT® Alpha-Strahlungstherapie gegen Krebs, hat seine Teilnahme an bevorstehenden Investorenkonferenzen im März 2025 angekündigt. Der CFO des Unternehmens, Raphi Levy, wird präsentieren und für persönliche Treffen mit Investoren zur Verfügung stehen.
Investoren, die an der Planung von Meetings mit Herrn Levy interessiert sind, können dies über ihre Vertreter bei Investor Summit Group, Oppenheimer und Sidoti koordinieren. Die Konferenzen bieten eine Gelegenheit für Investoren, mehr über die innovative Krebstechnologie von Alpha Tau und die Unternehmensentwicklungen zu erfahren.
- None.
- None.
JERUSALEM, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will present at the following investor conferences in March 2025.
| Event: | Investor Summit Event |
| Format: | Presentation |
| Date: | March 11, 2025 |
| Time: | 12:00PM – 12:30PM ET |
| Location: | Virtual |
| Event: | Oppenheimer 35th Annual Healthcare MedTech & Services Conference |
| Format: | Presentation |
| Date: | March 17, 2025 |
| Time: | 3:20PM – 3:50PM ET |
| Location: | Virtual |
| Event: | Sidoti Small Cap Conference |
| Format: | Presentation |
| Date: | March 19, 2025 |
| Time: | 11:30AM – 12:00PM ET |
| Location: | Virtual |
Mr. Levy will also be available for 1x1 investor meetings at the conferences. Please reach out to your Investor Summit Group, Oppenheimer, and Sidoti representatives to schedule.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
About Alpha DaRT®
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Investor Relations Contact:
FAQ
When will Alpha Tau Medical (DRTS) present at investor conferences in March 2025?
How can investors schedule 1-on-1 meetings with Alpha Tau (DRTS) management?
What is the main product being developed by Alpha Tau Medical (DRTS)?
Which investment firms are hosting Alpha Tau (DRTS) at their March 2025 conferences?
